Protein C News and Research

RSS

Insulin induces formation of new elastin in cultures of human aortic smooth muscle cells

New research reveals that insulin applied in therapeutic doses selectively stimulates the formation of new elastic fibers in cultures of human aortic smooth muscle cells.

10 Jan 2012

Life Technologies takes orders for new benchtop Ion Proton Sequencer

Life Technologies Corporation today announced it is taking orders for the new benchtop Ion Proton Sequencer that is designed to sequence the entire human genome in a day for $1,000.

10 Jan 2012

Researchers uncover exact function of LARGE enzyme linked with MD

Researchers at the University of Iowa have worked out the exact function of an enzyme that is critical for normal muscle structure and is involved in several muscular dystrophies. The findings, which were published Jan. 6 in the journal Science,, could be used to develop rapid, large-scale testing of potential muscular dystrophy therapies.

10 Jan 2012

USPTO issues patent to Lixte's lead compounds for treatment of neurological diseases

Lixte Biotechnology Holdings announces that the United States Patent and Trademark Office awarded a patent for the use of lead compounds from each of two different types of drugs, protein phosphatase inhibitors and histone deacetylase inhibitors, for the potential prevention and treatment of neurodegenerative diseases.

9 Jan 2012

Novel class of nanoparticles hold promise as a potential vehicle for drug delivery

In the images of fruit flies, clusters of neurons are all lit up, forming a brightly glowing network of highways within the brain. It’s exactly what University at Buffalo researcher Shermali Gunawardena was hoping to see: It meant that ORMOSIL, a novel class of nanoparticles, had successfully penetrated the insects’ brains. And even after long-term exposure, the cells and the flies themselves remained unharmed.

9 Jan 2012

Neomend receives PMA from FDA for Progel Extended Applicator Spray Tip

Neomend, Inc., a leading innovator in sealant and adhesion-prevention products for the surgical marketplace, said it has received premarket approval from the U.S. Food and Drug Administration for use of the company's new Progel Extended Applicator Spray Tip.

9 Jan 2012

Circadian initiates VGX-100 Phase 1 trial in advanced solid tumours

Circadian Technologies Limited announced today that it has commenced the first Phase 1 clinical trial of its fully human monoclonal antibody against VEGF-C, VGX-100, at a leading US-based cancer treatment centre.

9 Jan 2012

Scientists identify two genes involved in major symptoms of MeCP2 duplication disorder

The anxiety and behavioral issues associated with excess MeCP2 protein result from overexpression of two genes (Crh [corticotropin-releasing hormone] and Oprm 1 [mu-opioid receptor MOR 1]), which may point the way to treating these problems in patients with too much of the protein, said Baylor of Medicine scientists in a report that appears online in the journal Nature Genetics.

8 Jan 2012

AICAR therapy may combat heat stroke

We've all seen the story in the news before. Whether it's the death of a physically fit high school athlete at football training camp in August, or of an elderly woman gardening in the middle of the day in July, heat stroke is a serious, life-threatening condition for which there is no treatment beyond submersion in ice water or the application of ice packs to cool the body to a normal temperature.

8 Jan 2012

Proteomics: Thermo Fisher Scientific and PREMIER Biosoft to co-market SimGlycan software

Thermo Fisher Scientific Inc., the world leader in serving science, and PREMIER Biosoft, have announced an agreement to co-market PREMIER Biosoft’s SimGlycan® software. The agreement aims to advance glycobiology by dramatically speeding the characterization of complex glycans through automated interpretation of the rich data produced by Thermo Scientific mass spectrometer systems.

From Thermo Fisher Scientific Inc. 8 Jan 2012

New U.S. patent covers key element of Xencor's Xtend half-life prolongation technology

Xencor, Inc., a company using its proprietary Protein Design Automation (PDA) platform technology to engineer next-generation antibodies, announced today that the U.S. Patent and Trademark Office has issued Xencor a broad patent covering optimized monoclonal antibody variants and their application for extending in vivo half-life of antibodies.

7 Jan 2012

Silence completes siRNA research work with AstraZeneca, MedImmune

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces the successful completion of its research work under the Research Collaboration and Delivery Collaboration with its partner AstraZeneca and its biologics arm, MedImmune.

7 Jan 2012

Poor nutrition in the womb can increase risk of type 2 diabetes in later life

Researchers funded by the Biotechnology and Biological Sciences Research Council have shown one way in which poor nutrition in the womb can put a person at greater risk of developing type 2 diabetes and other age-related diseases in later life.

7 Jan 2012

Researchers crack structure and function of malarial protein

A biology lab at Washington University has just cracked the structure and function of a protein that plays a key role in the life of a parasite that killed 655,000 people in 2010.

7 Jan 2012

Studies identify genes and small molecules against protein conformational diseases

Two related studies from Northwestern University offer new strategies for tackling the challenges of preventing and treating diseases of protein folding, such as Alzheimer's, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis (ALS), cancer, cystic fibrosis and type 2 diabetes.

7 Jan 2012

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.

7 Jan 2012

AHA honors Rice University professor with Established Investigator Award

Rice University's Jane Grande-Allen, one of the world's foremost experts on the biomechanics of heart-valve tissue, has won an Established Investigator Award from the American Heart Association.

6 Jan 2012

Scripps professor receives pair of notable grants to study kinesin

Sathyanaryanan Puthanveettil, an assistant professor on the Florida campus of The Scripps Research Institute, has been awarded a pair of notable grants to study a critical component of long-term memory formation.

6 Jan 2012

Isis announces results from ISIS-TTRRx Phase 1 study on TTR amyloidosis

Isis Pharmaceuticals, Inc. announced today results from a Phase 1 study with ISIS-TTRRx. The results demonstrated that treatment with ISIS-TTRRx produced dose-dependent statistically significant reductions of greater than 80 percent in transthyretin (TTR) protein.

6 Jan 2012

Wake Forest Baptist participates in novel brain tumor vaccine clinical trial

A national clinical trial testing the efficacy of a novel brain tumor vaccine has begun at Wake Forest Baptist Medical Center, the only facility in the Southeast to participate.

6 Jan 2012

Protein C News and Research

Insulin induces formation of new elastin in cultures of human aortic smooth muscle cells

Life Technologies takes orders for new benchtop Ion Proton Sequencer

Researchers uncover exact function of LARGE enzyme linked with MD

USPTO issues patent to Lixte's lead compounds for treatment of neurological diseases

Novel class of nanoparticles hold promise as a potential vehicle for drug delivery

Neomend receives PMA from FDA for Progel Extended Applicator Spray Tip

Circadian initiates VGX-100 Phase 1 trial in advanced solid tumours

Scientists identify two genes involved in major symptoms of MeCP2 duplication disorder

AICAR therapy may combat heat stroke

Proteomics: Thermo Fisher Scientific and PREMIER Biosoft to co-market SimGlycan software

New U.S. patent covers key element of Xencor's Xtend half-life prolongation technology

Silence completes siRNA research work with AstraZeneca, MedImmune

Poor nutrition in the womb can increase risk of type 2 diabetes in later life

Researchers crack structure and function of malarial protein

Studies identify genes and small molecules against protein conformational diseases

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR

AHA honors Rice University professor with Established Investigator Award

Scripps professor receives pair of notable grants to study kinesin

Isis announces results from ISIS-TTRRx Phase 1 study on TTR amyloidosis

Wake Forest Baptist participates in novel brain tumor vaccine clinical trial

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News